Literature DB >> 11443553

Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate.

H D Davies1, C Adair, A McGeer, D Ma, S Robertson, M Mucenski, L Kowalsky, G Tyrell, C J Baker.   

Abstract

In a cohort study of 1207 pregnant women in Alberta, Canada, the serotype distributions of vaginal-rectal group B Streptococcus (GBS) isolates were compared with all isolates from neonates with invasive GBS disease identified by population-based surveillance. Serum concentrations of Ia, Ib, II, III, and V capsular polysaccharide (CPS)-specific IgG also were determined, according to serotype of the vaginal-rectal colonizing GBS strain. GBS colonization was detected in 19.5% (235 of 1207) of women. Serotype III accounted for 20.6% (48 of 233) of colonizing strains available for typing but for 37% (27 of 73) of invasive isolates from neonates (P<.01). Maternal colonization with type III was least likely to be associated with moderate concentrations of III CPS-specific IgG. Serotype III GBS is more invasive than other serotypes in this population; this may be due, at least in part, to poor maternal type III CPS-specific antibody response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443553     DOI: 10.1086/322029

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Prevalence of group B streptococcal type VI capsular IgG antibodies in Japan.

Authors:  K Matsubara; K Katayama; K Baba; H Nigami; H Harigaya
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-24       Impact factor: 3.267

2.  Preventing group B streptococcal infections: new recommendations.

Authors:  H Dele Davies
Journal:  Can J Infect Dis       Date:  2002-07

3.  Preventing group B streptococcal infections: New recommendations.

Authors:  H Dele Davies
Journal:  Paediatr Child Health       Date:  2002-07       Impact factor: 2.253

4.  Asymptomatic carriage of group A streptococcus is associated with elimination of capsule production.

Authors:  Anthony R Flores; Brittany E Jewell; Randall J Olsen; Samuel A Shelburne; Nahuel Fittipaldi; Stephen B Beres; James M Musser
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

5.  The impact of Lactobacillus on group B streptococcal interactions with cells of the extraplacental membranes.

Authors:  Megan Shiroda; David M Aronoff; Jennifer A Gaddy; Shannon D Manning
Journal:  Microb Pathog       Date:  2020-08-21       Impact factor: 3.738

6.  A Nonhemolytic Group B Streptococcus Strain Exhibits Hypervirulence.

Authors:  Claire Gendrin; Jay Vornhagen; Blair Armistead; Pallavi Singh; Christopher Whidbey; Sean Merillat; David Knupp; Robert Parker; Lisa M Rogers; Phoenicia Quach; Lakshminarayan M Iyer; L Aravind; Shannon D Manning; David M Aronoff; Lakshmi Rajagopal
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

7.  Differing mechanisms of surviving phagosomal stress among group B Streptococcus strains of varying genotypes.

Authors:  Michelle L Korir; Clare Laut; Lisa M Rogers; Jessica A Plemmons; David M Aronoff; Shannon D Manning
Journal:  Virulence       Date:  2016-10-28       Impact factor: 5.882

8.  Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease.

Authors:  Pia S Pannaraj; Joanna K Kelly; Marcia A Rench; Lawrence C Madoff; Morven S Edwards; Carol J Baker
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

9.  Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci.

Authors:  Hiroshige Mikamo; Atul K Johri; Lawrence C Paoletti; Lawrence C Madoff; Andrew B Onderdonk
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Whole-genome shotgun sequencing of a colonizing multilocus sequence type 17 Streptococcus agalactiae strain.

Authors:  Pallavi Singh; A Cody Springman; H Dele Davies; Shannon D Manning
Journal:  J Bacteriol       Date:  2012-11       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.